Vimta Labs Limited (VIMTALABS.NS)
INR 1016.0
(2.42%)
INR 1016.0
(2.42%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 986.72 Million INR | -55.51% |
| 2022 | 2.44 Billion INR | 24.19% |
| 2021 | 1.96 Billion INR | 33.43% |
| 2020 | 1.47 Billion INR | 16.17% |
| 2019 | 1.26 Billion INR | -17.7% |
| 2018 | 1.54 Billion INR | 17.88% |
| 2017 | 1.3 Billion INR | 26.83% |
| 2016 | 1.03 Billion INR | 30.94% |
| 2015 | 787.76 Million INR | 10.58% |
| 2014 | 712.36 Million INR | -5.06% |
| 2013 | 750.31 Million INR | 14.26% |
| 2012 | 656.65 Million INR | 44.22% |
| 2011 | 455.31 Million INR | -28.79% |
| 2010 | 639.37 Million INR | 12.23% |
| 2009 | 569.69 Million INR | -30.19% |
| 2008 | 816.03 Million INR | 6.4% |
| 2007 | 766.93 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 303.06 Million INR | 0.57% |
| 2023 Q1 | 297.56 Million INR | -52.66% |
| 2023 Q2 | 551.25 Million INR | 85.26% |
| 2023 Q4 | 301.33 Million INR | -51.39% |
| 2023 Q3 | 619.84 Million INR | 12.44% |
| 2023 FY | 1.08 Billion INR | -55.51% |
| 2022 Q3 | 585.79 Million INR | -7.19% |
| 2022 Q4 | 628.51 Million INR | 7.29% |
| 2022 FY | 2.44 Billion INR | 24.19% |
| 2022 Q1 | 597.93 Million INR | 9.83% |
| 2022 Q2 | 631.15 Million INR | 5.56% |
| 2021 FY | 1.96 Billion INR | 33.43% |
| 2021 Q1 | 440.46 Million INR | 7.67% |
| 2021 Q2 | 491.18 Million INR | 11.52% |
| 2021 Q4 | 544.39 Million INR | 10.78% |
| 2021 Q3 | 491.43 Million INR | 0.05% |
| 2020 Q4 | 409.08 Million INR | -3.07% |
| 2020 Q2 | 414.21 Million INR | 80.73% |
| 2020 Q1 | 229.19 Million INR | -23.53% |
| 2020 FY | 1.47 Billion INR | 16.17% |
| 2020 Q3 | 422.05 Million INR | 1.89% |
| 2019 Q2 | 298.61 Million INR | -3.11% |
| 2019 Q4 | 299.71 Million INR | -18.58% |
| 2019 FY | 1.26 Billion INR | -17.7% |
| 2019 Q1 | 308.21 Million INR | -16.63% |
| 2019 Q3 | 368.09 Million INR | 23.27% |
| 2018 Q4 | 369.7 Million INR | -1.96% |
| 2018 FY | 1.54 Billion INR | 17.88% |
| 2018 Q3 | 377.09 Million INR | -5.88% |
| 2018 Q2 | 400.66 Million INR | 1.5% |
| 2018 Q1 | 394.75 Million INR | 3.01% |
| 2017 Q1 | 265.34 Million INR | -6.33% |
| 2017 Q4 | 383.2 Million INR | 9.61% |
| 2017 FY | 1.3 Billion INR | 26.83% |
| 2017 Q3 | 349.59 Million INR | 12.72% |
| 2017 Q2 | 310.15 Million INR | 16.89% |
| 2016 Q2 | 299.83 Million INR | 2.31% |
| 2016 Q1 | 293.07 Million INR | 288.1% |
| 2016 Q4 | 283.27 Million INR | -8.54% |
| 2016 FY | 1.03 Billion INR | 30.94% |
| 2016 Q3 | 309.7 Million INR | 3.29% |
| 2015 FY | 787.76 Million INR | 10.58% |
| 2015 Q4 | 75.51 Million INR | -68.47% |
| 2015 Q2 | 256.81 Million INR | 18.95% |
| 2015 Q3 | 239.53 Million INR | -6.73% |
| 2015 Q1 | 215.9 Million INR | 232.97% |
| 2014 Q3 | 202.29 Million INR | -4.27% |
| 2014 Q4 | 64.84 Million INR | -67.95% |
| 2014 Q2 | 211.31 Million INR | -9.66% |
| 2014 FY | 712.36 Million INR | -5.06% |
| 2014 Q1 | 233.9 Million INR | 630.43% |
| 2013 Q2 | 241.92 Million INR | 9.13% |
| 2013 Q4 | 32.02 Million INR | -87.43% |
| 2013 FY | 750.31 Million INR | 14.26% |
| 2013 Q3 | 254.68 Million INR | 5.28% |
| 2013 Q1 | 221.67 Million INR | 342.56% |
| 2012 Q4 | 50.08 Million INR | -75.1% |
| 2012 FY | 656.65 Million INR | 44.22% |
| 2012 Q1 | 194.27 Million INR | 2583.73% |
| 2012 Q3 | 201.15 Million INR | -4.73% |
| 2012 Q2 | 211.13 Million INR | 8.68% |
| 2011 FY | 455.31 Million INR | -28.79% |
| 2011 Q4 | -7.82 Million INR | -105.06% |
| 2011 Q3 | 154.48 Million INR | 9.37% |
| 2011 Q2 | 141.24 Million INR | 0.0% |
| 2010 FY | 639.37 Million INR | 12.23% |
| 2009 FY | 569.69 Million INR | -30.19% |
| 2008 FY | 816.03 Million INR | 6.4% |
| 2007 FY | 766.93 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Krsnaa Diagnostics Limited | 4.13 Billion INR | 76.116% |
| Dr. Lal PathLabs Limited | 14.62 Billion INR | 93.252% |
| Metropolis Healthcare Limited | 5.81 Billion INR | 83.026% |
| Thyrocare Technologies Limited | 2.5 Billion INR | 60.58% |
| Vijaya Diagnostic Centre Limited | 4.82 Billion INR | 79.544% |